{
    "eid": "2-s2.0-85097511416",
    "title": "Practical Recommendations for the Topical Treatment of Atopic Dermatitis in South and East Asia",
    "cover-date": "2021-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Dermatology",
            "@code": "2708",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Algorithm",
        "Atopic dermatitis",
        "Pimecrolimus",
        "South and East Asia",
        "Tacrolimus"
    ],
    "authors": [
        "David Luk",
        "Kam Lun Ellis Hon",
        "Maria Victoria C. Dizon",
        "Kin Fon Leong",
        "Yong Kwang Tay",
        "Mark Jean Aan Koh",
        "Nisha Suyien Chandran",
        "Siriwan Wananukul",
        "Susheera Chatproedprai",
        "Thomas Luger"
    ],
    "citedby-count": 8,
    "ref-count": 98,
    "ref-list": [
        "Atopic dermatitis",
        "Atopic dermatitis",
        "The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization",
        "Prevalence and descriptive epidemiology of atopic dermatitis and its impact on quality of life in Singapore",
        "Prevalence of atopic dermatitis and pattern of drug therapy in malaysian children",
        "Prevalence of atopic dermatitis in Korea: Analysis by using national statistics",
        "Investigating international time trends in the incidence and prevalence of atopic eczema 1990\u20132010: a systematic review of epidemiological studies",
        "The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children",
        "Linking air pollution to atopic dermatitis",
        "The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin",
        "Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations",
        "Filaggrin gene mutation c.3321delA is associated with various clinical features of atopic dermatitis in the Chinese Han population",
        "A study on the knowledge, attitudes and practices of Southeast Asian dermatologists in the management of atopic dermatitis",
        "Eczema therapeutics in children: what do the clinical trials say?",
        "Investigation on Chinese herbal medicine for primary dysmenorrhea: implication from a nationwide prescription database in Taiwan",
        "Association between nine types of TCM constitution and five chronic diseases: a correspondence analysis based on a sample of 2,660 participants",
        "Complementary, alternative and integrative medicine for childhood atopic dermatitis",
        "Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas",
        "Assessment of \"corticophobia\" as an indicator of non-adherence to topical corticosteroids: a pilot study",
        "Guidelines for treatment of atopic eczema (atopic dermatitis) Part II",
        "Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches",
        "Guidelines for the management of atopic dermatitis in Singapore",
        "Clinical guidelines on management of atopic dermatitis in children",
        "Guidelines for treatment of atopic eczema (atopic dermatitis) part I",
        "Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents",
        "Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I",
        "A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas",
        "Translating atopic dermatitis management guidelines into practice for primary care providers",
        "Eczematous reactions to food in atopic eczema: position paper of the EAACI and GA2LEN",
        "Barrier repair therapy in atopic dermatitis: an overview",
        "Emollient treatment of atopic dermatitis: latest evidence and clinical considerations",
        "Management of atopic dermatitis in Japan",
        "Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis",
        "Evidence that human skin microbiome dysbiosis promotes atopic dermatitis",
        "Clinical Signs, staphylococcus and atopic eczema-related seromarkers",
        "A clinician\u2019s reference guide for the management of atopic dermatitis in Asians",
        "Japanese guidelines for atopic dermatitis 2017",
        "Scoping systematic review of treatments for eczema",
        "Clinical practice guidelines for the management of atopic dermatitis 2016",
        "Consensus guidelines for the treatment of atopic dermatitis in Korea (Part I): General management and topical treatment",
        "Elidel 1% Summary of Product Characteristics (Brazil)",
        "Elidel 1% Summary of Product Characteristics (Philippines)",
        "Elidel 1% Prescribing Information (Russia)",
        "Elidel 1% Summary of Product Characteristics (Indonesia)",
        "Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience",
        "Topical corticosteroid phobia in atopic dermatitis: A systematic review",
        "Topical corticosteroid phobia among parents of children with atopic eczema in Korea",
        "Factors associated with steroid phobia in caregivers of children with atopic dermatitis",
        "Correlations among steroid fear, acceptability, usage frequency, quality of life and disease severity in childhood eczema",
        "Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study",
        "Recent advances in pharmacotherapeutic paradigm of mild to recalcitrant atopic dermatitis",
        "Elidel highlights of prescribing information",
        "Protopic (Tacrolimus) prescribing information",
        "Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice",
        "Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis",
        "Topical calcineurin inhibitors in eczema and cancer association: a cohort study",
        "No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis",
        "Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies",
        "Dismissing the fallacies of childhood eczema management: case scenarios and an overview of best practices",
        "StabiEL: Stabilization of skin condition with Elidel\u2014a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid",
        "A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients",
        "Atopic dermatitis: Tacrolimus vs. topical corticosteroid use",
        "A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis",
        "A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis",
        "A study on the knowledge, attitudes, and practices of Asian dermatologists in the management of atopic dermatitis",
        "Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment",
        "Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug",
        "Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children",
        "Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial",
        "Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis",
        "Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use",
        "Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicentre, comparative studies",
        "Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study",
        "Overview of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas",
        "Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome",
        "Canadian practical guide for the treatment and management of atopic dermatitis",
        "Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants",
        "Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis",
        "Human epidermal Langerhans\u2019 cells are targets for the immunosuppressive macrolide tacrolimus (FK506)",
        "Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells",
        "Pimecrolimus does not affect Langerhans cells in murine epidermis",
        "Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis",
        "Pimecrolimus\u2014an anti-inflammatory drug targeting the skin",
        "Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus",
        "Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application",
        "A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis",
        "The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial",
        "Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease",
        "Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice",
        "A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids",
        "Crisaborole and its potential role in treating atopic dermatitis: Overview of early clinical studies",
        "Investigational drugs for atopic dermatitis",
        "Novel topical and systemic therapies in atopic dermatitis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Manila",
            "@id": "60071488",
            "affilname": "University of Santo Tomas, Manila",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071488",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60031325",
            "affilname": "National University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031325",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Kuala Lumpur",
            "@id": "60025530",
            "affilname": "Kuala Lumpur Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025530",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60015772",
            "affilname": "KK Women's And Children's Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015772",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60013022",
            "affilname": "Changi General Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013022",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60002798",
            "affilname": "Chinese University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002798",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60002469",
            "affilname": "United Christian Hospital Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002469",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Munster",
            "@id": "60000401",
            "affilname": "Westf\u00e4lische Wilhelms-Universit\u00e4t M\u00fcnster",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000401",
            "affiliation-country": "Germany"
        }
    ],
    "funding": [
        "Advisory Board member for Abbvie",
        "Meda Pharma S.p.A.",
        "UDG Healthcare plc",
        "Eli Lilly",
        "Pfizer",
        "GlaxoSmithKline",
        "Johnson & Johnson",
        "Celgene",
        "Janssen-Cilag",
        "GSK",
        "Astellas",
        "Beiersdorf and Menarini",
        "Menarini"
    ]
}